PURPOSE To guide clinicians and policymakers in three global resource-constrained
settings on treating patients with metastatic breast cancer (MBC) when Maximal setting …

Although not considered curative in nature, new therapeutic advances in metastatic breast
cancer (MBC) have substantially improved patient outcomes. This article discusses the state …

The selection of first-line chemotherapy for metastatic breast cancer (MBC) is complex
because of the myriad of treatment options available and the inherent biologic heterogeneity …

As therapeutic options have multiplied, chemotherapy for metastatic breast cancer (MBC)
has become increasingly complex. Furthermore, advances in the treatment of early-stage …

1013 Background: Improved survival in a randomized controlled trial is the gold standard for
drug approval in 1st line MBC. Time to progression (TTP) and progression-free survival …

Second consensus on medical treatment of metastatic breast cancer - ScienceDirect Skip to
main contentSkip to article Elsevier logo Journals & Books Search RegisterSign in View …

Treatment selection for metastatic breast cancer (MBC) is guided by multiple factors, most
importantly hormone receptor (HR) or HER2 expression, treatment history, and prognostic …

Purpose Oncologists, clinical trialists, and guideline developers need tools that enable them
to efficiently review the settings and results of previous studies testing metastatic breast …

Background Metastatic breast cancer (MBC) has become a chronic disease, with a median
overall survival (OS) of around 3 years and a 5-year survival rate of about 25%. OS are …

Background Patients with breast cancer are classified as having cells that over‐express the
human epidermal growth factor receptor 2 (known as HER2‐positive) or not (HER2 …